IMGN529 is an anti-CD37-maytansinoid conjugate with potent in vitro and in vivo activity against NHL and CLL cell lines

被引：0
|
作者：
Mayo, Michele F. [1 ]
Li, Min [1 ]
Yi, Yong [1 ]
Xu, Shanqin [1 ]
Lai, Katharine C. [1 ]
Erickson, Hans K. [1 ]
Deckert, Jutta [1 ]
Park, Peter U. [1 ]
Lutz, Robert J. [1 ]
Pinkas, Jan [1 ]
机构：
[1] ImmunoGen Inc, Waltham, MA USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-4581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4581
引用
收藏
页数：2
相关论文
共 43 条
  • [31] Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
    Horton, Holly M.
    Bernett, Matthew J.
    Peipp, Matthias
    Pong, Erik
    Karki, Sher
    Chu, Seung Y.
    Richards, John O.
    Chen, Hsing
    Repp, Roland
    Desjarlais, John R.
    Zhukovsky, Eugene A.
    BLOOD, 2010, 116 (16) : 3004 - 3012
  • [32] In-vitro and in-vivo anti-leukemic activity of a natural killer (NK) cell clone against both primary human leukemias and leukemic cell lines.
    Yan, Y
    McGuirk, J
    Steinherz, P
    OReilly, RJ
    BLOOD, 1996, 88 (10) : 968 - 968
  • [33] Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo
    Rennert, Paul D.
    Dufort, Fay J.
    Su, Lihe
    Sanford, Tom
    Birt, Alyssa
    Wu, Lan
    Lobb, Roy R.
    Ambrose, Christine
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 2071 - 2081
  • [34] Anti-GPRC5D/CD3 T cell-redirecting bispecific antibody with potent in vitro and in vivo antitumor efficacy against multiple myeloma.
    Kodama, Tatsushi
    Kochi, Yu
    Nakai, Waka
    Mizuno, Hideaki
    Baba, Takeshi
    Habu, Kiyoshi
    Sawada, Noriaki
    Tsunoda, Hiroyuki
    Shima, Takahiro
    Miyawaki, Kohta
    Kikushige, Yoshikane
    Mori, Yasuo
    Miyamoto, Toshihiro
    Maeda, Takahiro
    Akashi, Koichi
    CANCER RESEARCH, 2021, 81 (13)
  • [35] Oral administration of the opium alkaloid noscapine (NOS) exhibits potent anti-tumor activity against non-Hodgkin's lymphomas and myeloma cell lines in vitro and in vivo in SCID-beige murine xenograft models.
    O'Connor, O
    Mastrella, J
    Smith, E
    Toner, L
    Auerbach, A
    Leonard, JP
    BLOOD, 2005, 106 (11) : 682A - 682A
  • [36] Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies
    Hiemstra, Ida H.
    Engelberts, Patrick J.
    de Jong, Bart
    Schuurhuis, Danita H.
    Salcedo, Theodora W.
    Verploegen, Sandra
    van der Zee, Marten
    Gerritsen, Arnout F.
    Losic, Nedjad
    Horbach, Sjeng
    Oliveri, Roberto
    van Bueren, Jeroen J. Lammerts
    Usher, Pernille Autzen
    Schuurman, Janine
    Parren, Paul W. H. I.
    Breij, Esther C. W.
    BLOOD, 2018, 132
  • [37] CISH GENE-KNOCKOUT ANTI-CD70-CAR NK CELLS DEMONSTRATE POTENT ANTI-TUMOR ACTIVITY AGAINST SOLID TUMOR CELL LINES AND PROVIDE PARTIAL RESISTANCE TO TUMOR MICROENVIRONMENT INHIBITION
    Guo, Chao
    Fan, Yanying
    Aronov, Alexander
    Buren, Luxuan
    Xie, Ming-Hong
    Chan, Ivan
    Lazetic, Sasha
    Trager, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A123 - A123
  • [38] TXA9, a cardiac glycoside from Streptocaulon juventas, exerts a potent anti-tumor activity against human non-small cell lung cancer cells in vitro and in vivo
    Xue, Rui
    Han, Na
    Xia, Mingyu
    Ye, Chun
    Hao, Zhihui
    Wang, Lihui
    Wang, Yu
    Yang, Jingyu
    Saiki, Ikuo
    Yin, Jun
    STEROIDS, 2015, 94 : 51 - 59
  • [39] An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma
    Zhukovsky, Eugene A.
    Horton, Holly
    Peipp, Matthias
    Pong, Erik
    Bernett, Matthew
    Karki, Sher
    Richards, John
    Chu, Seung
    Repp, Roland
    Desjarlais, John
    BLOOD, 2008, 112 (11) : 325 - 326
  • [40] Potent anti-tumor activity against patient CLL, MM and AML by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d.
    Lameris, Roeland
    Ruben, Jurjen M.
    de Weerdt, Iris
    Roovers, Rob C.
    Kater, Arnon P.
    Riedl, Thilo A.
    Iglesias, Victoria
    Adang, Ton
    de Gruijl, Tanja D.
    Parren, Paul W. H. I.
    van der Vliet, Hans J.
    CANCER RESEARCH, 2021, 81 (13)
12345